Non-Muscle Invasive Bladder Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Prokarium Ltd., Vaxiion Therapeutics, Tyra Biosciences, Lipac Oncology, SURGE The

Non-Muscle Invasive Bladder Cancer Pipeline constitutes 20+ key companies continuously working towards developing 25+ Non-Muscle Invasive Bladder Cancer treatment therapies, analyzes DelveInsight.

Non-Muscle Invasive Bladder Cancer Overview:

Non-muscle invasive bladder cancer (NMIBC) is a diverse subset of urothelial carcinoma, with considerable variation in the likelihood of recurrence and progression to muscle-invasive disease. It develops in the bladder's inner lining and may present with symptoms or remain asymptomatic. Key warning signs include hematuria (blood in the urine), which is often painless, frequent and urgent urination, discomfort during urination, lower abdominal pain, and back pain.

Several risk factors increase the likelihood of developing bladder cancer. Smoking significantly raises the risk, with cigarette smokers being up to three times more likely to develop the disease. Additionally, advanced age, male gender, and other factors contribute to increased susceptibility. Most cases occur in individuals over 60, and men are three to four times more likely than women to be diagnosed with bladder cancer.

Bladder cancer diagnosis primarily relies on cystoscopy and histological analysis of resected tissue. Approximately 4% of cases are detected incidentally through imaging conducted for non-urological symptoms. Traditional white light cystoscopy (WLC) has a detection rate as low as 60%. However, improved visualization techniques, such as hexyl aminolevulinate (HAL)-photodynamic diagnosis (PDD) and narrow-band imaging (NBI), enhance tumor detection and aid in early recurrence identification. Blue light cystoscopy (BLC) or PDD requires the intravesical administration of HAL, a photosensitizing agent that accumulates in cancerous cells. Under blue light, these cells emit a red fluorescence, aiding in more precise tumor visualization.

Request for a detailed insights report on Non-Muscle Invasive Bladder Cancer pipeline insights @ https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Non-Muscle Invasive Bladder Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-Muscle Invasive Bladder Cancer Therapeutics Market.

Key Takeaways from the Non-Muscle Invasive Bladder Cancer Pipeline Report

DelveInsight's Non-Muscle Invasive Bladder Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Non-Muscle Invasive Bladder Cancer treatment.
Key Non-Muscle Invasive Bladder Cancer companies such as Prokarium Ltd., Vaxiion Therapeutics, Tyra Biosciences, Lipac Oncology, SURGE Therapeutics, Jiangsu Simcere Pharmaceutical, Shanghai Hengrui Pharmaceutical Co., enGene, and others are evaluating new drugs for Non-Muscle Invasive Bladder Cancer to improve the treatment landscape.
Promising Non-Muscle Invasive Bladder Cancer pipeline therapies in various stages of development include TAR-200, VAX 014, SIM0237, and others.

Recent breakthroughs in the Non-Muscle Invasive Bladder Cancer Pipeline Segment:
On April 22, 2024, the FDA approved Anktiva in combination with BCG for adults with BCG-unresponsive NMIBC with CIS, with or without papillary tumors. In a single-arm, multicenter trial of 77 patients, Anktiva demonstrated a CR rate of 62%, with 58% of responders maintaining CR for at least 12 months.
On December 16, 2022, the U.S. Food and Drug Administration (FDA) approved Adstiladrin, an adenoviral vector-based gene therapy, for adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with carcinoma in situ (CIS), with or without papillary tumors. In a multicenter, single-arm trial involving 157 patients, Adstiladrin achieved a complete response (CR) rate of 51%, with a median duration of response of 9.7 months.
Non-Muscle Invasive Bladder Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Non-Muscle Invasive Bladder Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Muscle Invasive Bladder Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Non-Muscle Invasive Bladder Cancer market.

Download our free sample page report on Non-Muscle Invasive Bladder Cancer pipeline insights @ https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-Muscle Invasive Bladder Cancer Emerging Drugs

TAR-200: TARIS Biomedical
VAX 014: Vaxiion Therapeutics
SIM0237: Simcere Pharmaceutical Group

Non-Muscle Invasive Bladder Cancer Companies

There are over 20 key companies currently developing therapies for Non-Muscle Invasive Bladder Cancer (NMIBC). Among them, TARIS Biomedical has a drug candidate in the most advanced stage of development, specifically Phase III.

DelveInsight's report covers around 25+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Non-Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Non-Muscle Invasive Bladder Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Non-Muscle Invasive Bladder Cancer Therapies and Key Companies: Non-Muscle Invasive Bladder Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-Muscle Invasive Bladder Cancer Pipeline Therapeutic Assessment
• Non-Muscle Invasive Bladder Cancer Assessment by Product Type
• Non-Muscle Invasive Bladder Cancer By Stage
• Non-Muscle Invasive Bladder Cancer Assessment by Route of Administration
• Non-Muscle Invasive Bladder Cancer Assessment by Molecule Type

Download Non-Muscle Invasive Bladder Cancer Sample report to know in detail about the Non-Muscle Invasive Bladder Cancer treatment market @ Non-Muscle Invasive Bladder Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Non-Muscle Invasive Bladder Cancer Current Treatment Patterns
4. Non-Muscle Invasive Bladder Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Non-Muscle Invasive Bladder Cancer Late-Stage Products (Phase-III)
7. Non-Muscle Invasive Bladder Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Muscle Invasive Bladder Cancer Discontinued Products
13. Non-Muscle Invasive Bladder Cancer Product Profiles
14. Non-Muscle Invasive Bladder Cancer Key Companies
15. Non-Muscle Invasive Bladder Cancer Key Products
16. Dormant and Discontinued Products
17. Non-Muscle Invasive Bladder Cancer Unmet Needs
18. Non-Muscle Invasive Bladder Cancer Future Perspectives
19. Non-Muscle Invasive Bladder Cancer Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Non-Muscle Invasive Bladder Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.